 The purpose of this study is to evaluate the usefulness of antifungal lock therapy with liposomal amphotericin B Ambisome, in combination with systemic antifungals, in patients with catheter-related blood stream infections with fungal organisms, whose catheter has not been removed because of the continuing critical need for central line access. The primary group of potential patients will be those with intestinal insufficiency, including post-op small bowel transplant recipients. 